Navigation Links
Nuvelo Announces Presentations on NU206 and rNAPc2 at 2008 American Association for Cancer Research Annual Meeting
Date:4/9/2008

SAN CARLOS, Calif., April 9, 2008 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: NUVO) today announced that preclinical data evaluating the mechanism of action and therapeutic potential of NU206 (R-spondin1) for chemotherapy or radiation-induced oral mucositis, and preclinical data evaluating recombinant nematode anticoagulant protein c2 (rNAPc2) in mouse models of colorectal cancer, will be presented at the 2008 American Association for Cancer Research (AACR) Annual Meeting, in San Diego, CA, April 12-16, 2008.

The presentation details are as follows:

Date/Time: Sunday, April 13, 2008, 1:00 - 5:00 p.m. PT

Poster Title (#1495): R-spondin1 protects mice from chemotherapy or radiation-induced oral mucositis by activating canonical Wnt/beta-catenin pathway

Location: Poster Board #2, Section 32, Exhibit Hall B-F, San Diego Convention Center

Date/Time: Wednesday, April 16, 2008, 8:00 a.m. - 12:00 p.m. PT

Poster Title (#5698): rNAPc2 inhibits colorectal cancer in mouse models through tissue factor

Location: Poster Board #11, Section 31, Exhibit Hall B-F, San Diego Convention Center

About Nuvelo

Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular disease, cancer and other debilitating medical conditions. Nuvelo's development pipeline includes NU172, a direct thrombin inhibitor in Phase 1 development for use as a potential short-acting anticoagulant during medical or surgical procedures; and preclinical candidate NU206, a Wnt pathway modulator for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease. In addition, Nuvelo is pur
'/>"/>

SOURCE Nuvelo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Nuvelo Announces Upcoming Conference Calls, Webcasts and Conference Participation
2. Nuvelo Announces Upcoming Conference Calls, Webcasts and Conference Participation
3. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
4. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
5. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
6. HEI, Inc. Announces Sale of RFID Division Assets
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
8. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
9. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
10. Brooke Franchise Corporation Announces Selected July Results
11. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 2Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 3VidaySalud.com(TM) Reaches 1,000,000 Page Views In its First Six Months of Operation 2The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 2The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 3The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 4The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 5CELLECTA INC to Develop New Approach for Cancer Gene Discovery in Partnership with Roswell Park Cancer Institute and Health Research Inc 14095 1CELLECTA INC to Develop New Approach for Cancer Gene Discovery in Partnership with Roswell Park Cancer Institute and Health Research Inc 14095 2CELLECTA INC to Develop New Approach for Cancer Gene Discovery in Partnership with Roswell Park Cancer Institute and Health Research Inc 14095 3Apollo PACS Inc Selected by Henry Ford Health System for Its Digital Pathology Solution 57359 1Apollo PACS Inc Selected by Henry Ford Health System for Its Digital Pathology Solution 57359 2Apollo PACS Inc Selected by Henry Ford Health System for Its Digital Pathology Solution 57359 3Health Leaders Issue Recommendations to Improve Management of a Common Costly and Misunderstood Cardiovascular Disease 3A Atrial Fibrillation 57357 1Health Leaders Issue Recommendations to Improve Management of a Common Costly and Misunderstood Cardiovascular Disease 3A Atrial Fibrillation 57357 2Health Leaders Issue Recommendations to Improve Management of a Common Costly and Misunderstood Cardiovascular Disease 3A Atrial Fibrillation 57357 3Health Leaders Issue Recommendations to Improve Management of a Common Costly and Misunderstood Cardiovascular Disease 3A Atrial Fibrillation 57357 4Health Leaders Issue Recommendations to Improve Management of a Common Costly and Misunderstood Cardiovascular Disease 3A Atrial Fibrillation 57357 5